Literature DB >> 22761271

Off spells and dyskinesias: pharmacologic management of motor complications.

Tarannum S Khan1.   

Abstract

There are two major causes of disability in patients with Parkinson disease: motor fluctuations that occur when a dose of levodopa becomes ineffective, leading to a "wearing off," and hyperkinetic movements (dyskinesias) caused by excessive levels of dopamine. The utility of continuous levodopa treatment is therefore limited by motor complications. Pharmacologic options to treat wearing off include adding (or increasing the dosage of) levodopa, adding (or increasing the dosage of) a dopamine agonist, or adjunctive treatment with a monoamine oxidase inhibitor or catechol-O-methyltransferase inhibitor. Dyskinesias will respond to a reduction in levodopa dosage at the expense of worsening parkinsonism and an increase in the number of "off" episodes. Continuous dopamine stimulation may overcome the pulsatile stimulation of postsynaptic dopamine receptors produced by standard oral formulations of levodopa that lead to motor complications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761271     DOI: 10.3949/ccjm.79.s2a.02

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  4 in total

1.  A new quantitative rating scale for dyskinesia in nonhuman primates.

Authors:  Lisa F Potts; Subramaniam Uthayathas; Alexander C M Greven; Bhagyalaxmi Dyavarshetty; Mary M Mouradian; Stella M Papa
Journal:  Behav Pharmacol       Date:  2015-02       Impact factor: 2.293

2.  Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-09

3.  Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-11

4.  Deep Brain Stimulation and Treatment Outcomes of Young- and Late-Onset (≤55 Years) Parkinson's Disease: A Population-Based Study.

Authors:  Emanuele Camerucci; Cole D Stang; Pierpaolo Turcano; Philip W Tipton; James H Bower; Anhar Hassan; Bryan T Klassen; Rodolfo Savica
Journal:  Front Neurol       Date:  2021-12-10       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.